Oruka Therapeutics (NASDAQ:ORKA) Director Carl Dambkowski Sells 12,583 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the transaction, the director directly owned 38,743 shares in the company, valued at approximately $2,716,271.73. The trade was a 24.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, June 11th, Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock. The stock was sold at an average price of $70.13, for a total transaction of $1,572,104.21.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $58.97, for a total transaction of $6,191,850.00.

Oruka Therapeutics Trading Up 2.1%

NASDAQ ORKA opened at $69.89 on Friday. The firm’s fifty day moving average price is $63.40 and its two-hundred day moving average price is $43.94. Oruka Therapeutics, Inc. has a 1 year low of $10.77 and a 1 year high of $91.00. The firm has a market capitalization of $4.22 billion, a P/E ratio of -36.03 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, research analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating on shares of Oruka Therapeutics in a report on Wednesday, June 3rd. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a report on Monday, April 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, Piper Sandler restated an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.30.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada lifted its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the period. Kennedy Capital Management LLC lifted its position in Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares during the period. AlphaCentric Advisors LLC lifted its position in Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after purchasing an additional 626 shares during the period. Russell Investments Group Ltd. lifted its position in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after purchasing an additional 788 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after acquiring an additional 904 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.